Perspectives on Biomarker and Surrogate Endpoint Evaluation Discussion Forum Summary (2011) / Chapter Skim
Currently Skimming:
Appendix A: Discussion Forum Agenda
Appendix A: Discussion Forum Agenda
Pages 113-114
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 113... ...
Wagner, Recommendations 1–2, the Evaluation Framework 9:10 am Ronald Krauss and Maria Lopes-Virella, LDL and HDL Case Study 9:30 am Roberta Ness, Recommendations 3–6 9:50 am Panel discussion 10:30 am Session 2: FDA and NIH Perspectives 10:30 am Kathleen Ellwood and Paula Trumbo, CFSAN: Current biomarker processes at FDA and basis for IOM study 10:45 am Michael Lauer, Division of Cardiovascular Sciences, NHLBI, NIH 11:00 am Paul Coates, NIH Office of Dietary Supplements 11:15 am BREAK 11:30 am Marc Walton, CDER: Biomarker Qualification in CDER 11:45 am Robert Becker, CDRH: Biomarkers for Devices 12:00 pm LUNCH 12:15 pm Session 2 Panel discussion Moderated by Roberta Ness 11
|
From page 114... ...
Ball, committee chair 9:30 am Session 5: Session for Stakeholder Comments -minute reactions to report recommendations 9:45 am James Mayne, Pfizer 9:50 am Melissa Musiker, Grocery Manufacturers Association 9:55 am Federico Goodsaid, Food and Drug Administration 11:45 am Wrap-up John R Ball, committee chair 12:00 pm ADJOURN MEETING
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.